Literature DB >> 16541218

Diffuse structural and metabolic brain changes in Fabry disease.

Silvia Marino1, Walter Borsini, Susanna Buchner, Marzia Mortilla, Maria L Stromillo, Marco Battaglini, Antonio Giorgio, Placido Bramanti, Antonio Federico, Nicola De Stefano.   

Abstract

OBJECTIVES: To assess structural and metabolic brain changes in subjects affected by Fabry disease (FD) or carrying the disease mutation.
BACKGROUND: FD is an X-linked metabolic disorder due to alpha-galactosidase A deficiency, which leads to storage of glycosphingolipids in many tissues and organs. Previous MR studies have shown structural and metabolic brain abnormalities in FD patients. It is not clear, however, whether tissue damage can be seen in both the brains of hemizygous and heterozygous and whether quantitative MR metrics are useful to monitor disease evolution. DESIGN/
METHODS: We studied 4 males and 4 females with FD. Each subject underwent brain proton MRI/MR spectroscopic imaging (MRSI) examinations to obtain measures of total brain volumes, total brain lesion volumes, magnetization transfer ratios (MTr) in WM and central brain levels of N-acetylaspartate (NAA) to creatine (Cr). A second MR examination was performed in five subjects after 2 years.
RESULTS: Focal WM lesions were found in 2 males and 1 female. The MTr values were always low in the WM lesions of FD subjects (p < 0.001) and also were low in the normal-appearing WM of 2 affected males. Total brain volumes were never decreased in FD subjects. Brain NAA/Cr values were significantly (p = 0.005) lower in FD subjects than in normal controls and correlated closely with Rankin scale measures (r = -0.79). On follow-up examinations, no significant MR changes were found. However, the small changes in NAA/Cr correlated closely with changes in Rankin scores (r = -0.86).
CONCLUSIONS: Subtle structural and metabolic tissue damage can extend beyond WM lesions in FD subjects. Diffuse brain NAA/Cr decrease can be found in FD subjects in relation to the degree of their CNS involvement and its evolution over time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541218     DOI: 10.1007/s00415-005-0020-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Normalized accurate measurement of longitudinal brain change.

Authors:  S M Smith; N De Stefano; M Jenkinson; P M Matthews
Journal:  J Comput Assist Tomogr       Date:  2001 May-Jun       Impact factor: 1.826

2.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

Authors:  S Narayanan; N De Stefano; G S Francis; R Arnaoutelis; Z Caramanos; D L Collins; D Pelletier; J P Antel; D L Arnold
Journal:  J Neurol       Date:  2001-11       Impact factor: 4.849

3.  Correlations between clinical findings and magnetization transfer imaging metrics of tissue damage in individuals with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Authors:  G Iannucci; M Dichgans; M Rovaris; R Brüning; T Gasser; L Giacomotti; T A Yousry; M Filippi
Journal:  Stroke       Date:  2001-03       Impact factor: 7.914

4.  Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy.

Authors:  J Vion-Dury; F Nicoli; A M Salvan; S Confort-Gouny; C Dhiver; P J Cozzone
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

5.  Pulsed magnetization transfer spin-echo MR imaging.

Authors:  G B Pike; G H Glover; B S Hu; D R Enzmann
Journal:  J Magn Reson Imaging       Date:  1993 May-Jun       Impact factor: 4.813

6.  Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study.

Authors:  G Tedeschi; S Bonavita; T K Banerjee; A Virta; R Schiffmann
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

7.  Cognitive decline in AD and mild cognitive impairment is associated with global brain damage.

Authors:  W M Van Der Flier; D M J Van Den Heuvel; A W E Weverling-Rijnsburger; A Spilt; E L E M Bollen; R G J Westendorp; H A M Middelkoop; M A Van Buchem
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

8.  Homocysteine, cerebrovascular disease and brain atrophy.

Authors:  Perminder Sachdev
Journal:  J Neurol Sci       Date:  2004-11-15       Impact factor: 3.181

9.  Anderson-Fabry disease with cerebrovascular complications in two Italian families.

Authors:  W Borsini; G Giuliacci; F Torricelli; E Pelo; F Martinelli; M R Scordo
Journal:  Neurol Sci       Date:  2002-06       Impact factor: 3.307

10.  Imaging cerebral atrophy: normal ageing to Alzheimer's disease.

Authors:  Nick C Fox; Jonathan M Schott
Journal:  Lancet       Date:  2004-01-31       Impact factor: 79.321

View more
  9 in total

Review 1.  Stroke and Fabry disease.

Authors:  Miguel Viana-Baptista
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

2.  Diffusion tensor imaging and brain volumetry in Fabry disease patients.

Authors:  Teemu Paavilainen; Virva Lepomäki; Jani Saunavaara; Ronald Borra; Pirjo Nuutila; Ilkka Kantola; Riitta Parkkola
Journal:  Neuroradiology       Date:  2013-01-05       Impact factor: 2.804

3.  Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome).

Authors:  James E Davison; Christian J Hendriksz; Yu Sun; Nigel P Davies; Paul Gissen; Andrew C Peet
Journal:  J Inherit Metab Dis       Date:  2010-10-01       Impact factor: 4.982

4.  Detecting the effects of Fabry disease in the adult human brain with diffusion tensor imaging and fast bound-pool fraction imaging.

Authors:  Hunter R Underhill; Katie Golden-Grant; Lauren T Garrett; Stefanie Uhrich; Brandon A Zielinski; C Ronald Scott
Journal:  J Magn Reson Imaging       Date:  2015-05-27       Impact factor: 4.813

Review 5.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 6.  Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve.

Authors:  Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

7.  Fabry disease and early stroke.

Authors:  U Feldt-Rasmussen
Journal:  Stroke Res Treat       Date:  2011-06-23

Review 8.  Neuroimaging in Fabry disease: current knowledge and future directions.

Authors:  Sirio Cocozza; Camilla Russo; Giuseppe Pontillo; Antonio Pisani; Arturo Brunetti
Journal:  Insights Imaging       Date:  2018-11-02

Review 9.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.